Nadine Jagerovic

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8446227/publications.pdf

Version: 2024-02-01

98 papers	2,630 citations	147801 31 h-index	233421 45 g-index
104 all docs	104 docs citations	104 times ranked	3091 citing authors

#	Article	IF	Citations
1	The Binding Mode to Orthosteric Sites and/or Exosites Underlies the Therapeutic Potential of Drugs Targeting Cannabinoid CB2 Receptors. Frontiers in Pharmacology, 2022, 13, 852631.	3.5	2
2	Targeting CB2 and TRPV1: Computational Approaches for the Identification of Dual Modulators. Frontiers in Molecular Biosciences, 2022, 9, 841190.	3.5	3
3	Relevance of Peroxisome Proliferator Activated Receptors in Multitarget Paradigm Associated with the Endocannabinoid System. International Journal of Molecular Sciences, 2021, 22, 1001.	4.1	23
4	Palmitoleoylethanolamide Is an Efficient Anti-Obesity Endogenous Compound: Comparison with Oleylethanolamide in Diet-Induced Obesity. Nutrients, 2021, 13, 2589.	4.1	14
5	Synthetic and Natural Derivatives of Cannabidiol. Advances in Experimental Medicine and Biology, 2021, 1297, 11-25.	1.6	6
6	Preclinical Investigation in Neuroprotective Effects of the GPR55 Ligand VCE-006.1 in Experimental Models of Parkinsonâ€™s Disease and Amyotrophic Lateral Sclerosis. Molecules, 2021, 26, 7643.	3.8	10
7	Discovery of Homobivalent Bitopic Ligands of the Cannabinoid CB₂ Receptor**. Chemistry - A European Journal, 2020, 26, 15839-15842.	3.3	20
8	Therapeutic Exploitation of GPR18: Beyond the Cannabinoids?. Journal of Medicinal Chemistry, 2020, 63, 14216-14227.	6.4	31
9	Novel approaches and current challenges with targeting the endocannabinoid system. Expert Opinion on Drug Discovery, 2020, 15, 917-930.	5.0	23
10	Antitumor Cannabinoid Chemotypes: Structural Insights. Frontiers in Pharmacology, 2019, 10, 621.	3.5	24
11	Increased expression of cannabinoid CB2 and serotonin 5-HT1A heteroreceptor complexes in a model of newborn hypoxic-ischemic brain damage. Neuropharmacology, 2019, 152, 58-66.	4.1	25
12	Cannabidiol skews biased agonism at cannabinoid CB1 and CB2 receptors with smaller effect in CB1-CB2 heteroreceptor complexes. Biochemical Pharmacology, 2018, 157, 148-158.	4.4	74
13	Emerging strategies targeting CB2 cannabinoid receptor: Biased agonism and allosterism. Biochemical Pharmacology, 2018, 157, 8-17.	4.4	40
14	New pyridazinone-4-carboxamides as new cannabinoid receptor type-2 inverse agonists: Synthesis, pharmacological data and molecular docking. European Journal of Medicinal Chemistry, 2017, 127, 398-412.	5.5	15
15	Synthesis of a novel CB2 cannabinoid-porphyrin conjugate based on an antitumor chromenopyrazoledione. Journal of Porphyrins and Phthalocyanines, 2017, 21, 67-76.	0.8	4
16	New Methods for the Synthesis of Cannabidiol Derivatives. Methods in Enzymology, 2017, 593, 237-257.	1.0	8
17	An Overview on Medicinal Chemistry of Synthetic and Natural Derivatives of Cannabidiol. Frontiers in Pharmacology, 2017, 8, 422.	3.5	123
18	In Vitro Primary Screening of a Synthetic Series of Chromenoazoldiones against Trypanosoma cruzi. Proceedings (mdpi), 2017, 1, .	0.2	0

#	Article	IF	Citations
19	Benzyl-1,2,4-triazoles as CB1 Cannabinoid Receptor Ligands: Preparation and In Vitro Pharmacological Evaluation. International Journal of Medicinal Chemistry, 2016, 2016, 1-9.	2.2	0
20	Targeting Cannabinoid CB2 Receptors in the Central Nervous System. Medicinal Chemistry Approaches with Focus on Neurodegenerative Disorders. Frontiers in Neuroscience, 2016, 10, 406.	2.8	108
21	Antichagasic and trichomonacidal activity of 1-substituted 2-benzyl-5-nitroindazolin-3-ones and 3-alkoxy-2-benzyl-5-nitro-2H-indazoles. European Journal of Medicinal Chemistry, 2016, 115, 295-310.	5.5	29
22	Cannabinoid receptor 2 (CB₂) agonists and antagonists: a patent update. Expert Opinion on Therapeutic Patents, 2016, 26, 843-856.	5.0	56
23	A critical review of both the synthesis approach and the receptor profile of the 8-chloro-1-(2â€²,4â€²-dichlorophenyl)-N-piperidin-1-yl-1,4,5,6-tetrahydrobenzo[6,7]cyclohepta[1,2-c]pyrazole-3-carboxamide and analogue derivatives. European Journal of Medicinal Chemistry, 2016, 121, 194-208.	5.5	6
24	Exploring the Benzimidazole Ring as a Substitution for Indole in Cannabinoid Allosteric Modulators. Cannabis and Cannabinoid Research, 2016, 1, 196-201.	2.9	2
25	Chromenopyrazole, a Versatile Cannabinoid Scaffold with in Vivo Activity in a Model of Multiple Sclerosis. Journal of Medicinal Chemistry, 2016, 59, 6753-6771.	6.4	34
26	Identification of Novel GPR55 Modulators Using Cell-Impedance-Based Label-Free Technology. Journal of Medicinal Chemistry, 2016, 59, 1840-1853.	6.4	12
27	Allosteric Modulators of the CB₁ Cannabinoid Receptor: A Structural Update Review. Cannabis and Cannabinoid Research, 2016, 1, 22-30.	2.9	69
28	Biological characterization of PM226, a chromenoisoxazole, as a selective CB 2 receptor agonist with neuroprotective profile. Pharmacological Research, 2016, 110, 205-215.	7.1	25
29	Advances Towards The Discovery of GPR55 Ligands. Current Medicinal Chemistry, 2016, 23, 2087-2100.	2.4	35
30	Selective, Nontoxic CB₂ Cannabinoid o-Quinone with in Vivo Activity against Triple-Negative Breast Cancer. Journal of Medicinal Chemistry, 2015, 58, 2256-2264.	6.4	33
31	Synthesis, pharmacological evaluation and docking studies of pyrrole structure-based CB 2 receptor antagonists. European Journal of Medicinal Chemistry, 2015, 101, 651-667.	5.5	14
32	Combining rimonabant and fentanyl in a single entity: preparation and pharmacological results. Drug Design, Development and Therapy, 2014, 8, 263.	4.3	13
33	Preparation of 2,2-dimethylchroman-4-ones from 5-alkyl-substituted resorcinols: microwave-assisted synthesis and theoretical calculations. Arkivoc, 2014, 2014, 319-332.	0.5	2
34	Synthetic cannabinoid quinones: Preparation, inÂvitro antiproliferative effects and inÂvivo prostate antitumor activity. European Journal of Medicinal Chemistry, 2013, 70, 111-119.	5.5	42
35	Description of a Bivalent Cannabinoid Ligand with Hypophagic Properties. Archiv Der Pharmazie, 2013, 346, 171-179.	4.1	12
36	Novel antiobesity agents: Synthesis and pharmacological evaluation of analogues of Rimonabant and of LH21. Bioorganic and Medicinal Chemistry, 2013, 21, 1708-1716.	3.0	19

#	Article	IF	Citations
37	Ghrelin-Induced Orexigenic Effect in Rats Depends on the Metabolic Status and Is Counteracted by Peripheral CB1 Receptor Antagonism. PLoS ONE, 2013, 8, e60918.	2.5	33
38	Antiâ€obesity efficacy of LHâ€21, a cannabinoid CB₁ receptor antagonist with poor brain penetration, in dietâ€induced obese rats. British Journal of Pharmacology, 2012, 165, 2274-2291.	5.4	51
39	Chromenopyrazoles: Nonâ€psychoactive and Selective CB₁ Cannabinoid Agonists with Peripheral Antinociceptive Properties. ChemMedChem, 2012, 7, 452-463.	3.2	27
40	Inside Back Cover: Chromenopyrazoles: Non-psychoactive and Selective CB1Cannabinoid Agonists with Peripheral Antinociceptive Properties (ChemMedChem 3/2012). ChemMedChem, 2012, 7, 536-536.	3.2	0
41	Tautomerism of hydroxychromenopyrazoles. Journal of Molecular Structure, 2012, 1015, 162-165.	3.6	1
42	Determination of the absolute configuration of 1,3,5-triphenyl-4,5-dihydropyrazole enantiomers by a combination of VCD, ECD measurements, and theoretical calculations. Tetrahedron: Asymmetry, 2011, 22, 1120-1124.	1.8	11
43	Antiprotozoal Activity of 1-Phenethyl-4-Aminopiperidine Derivatives. Antimicrobial Agents and Chemotherapy, 2009, 53, 3815-3821.	3.2	18
44	Novel derivatives of 3-alkyl-1,5-diaryl-1H-1,2,4-triazoles and their pharmacological evaluation as CB1 cannabinoid ligands. Monatshefte FÃ¼r Chemie, 2008, 139, 1073-1082.	1.8	5
45	Antiobesity designed multiple ligands: Synthesis of pyrazole fatty acid amides and evaluation as hypophagic agents. Bioorganic and Medicinal Chemistry, 2008, 16, 10098-10105.	3.0	33
46	Analgesic activity and pharmacological characterization of N-[1-phenylpyrazol-3-yl]-N-[1-(2-phenethyl)-4-piperidyl] propenamide, a new opioid agonist acting peripherally. European Journal of Pharmacology, 2008, 595, 22-29.	3.5	12
47	CB1 Cannabinoid Antagonists: Structure-Activity Relationships and Potential Therapeutic Applications. Current Topics in Medicinal Chemistry, 2008, 8, 205-230.	2.1	54
48	Synthesis and Pharmacological Evaluation of Chlorinated N-Alkyl-3- and -5-(2-hydroxyphenyl)pyrazoles as CB 1 Cannabinoid Ligands. Monatshefte FÃ¼r Chemie, 2007, 138, 797-811.	1.8	14
49	Antiobesity effects of the novel in vivo neutral cannabinoid receptor antagonist 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1H-1,2,4-triazole â€“ LH 21. Neuropharmacology, 2006, 51, 358-366.	4.1	116
50	Structuralâ€“activity relationship study onÂC-4Âcarbon atom ofÂtheÂCB1 antagonist SR141716: synthesis andÂpharmacological evaluation ofÂ1,2,4-triazole-3-carboxamides. European Journal of Medicinal Chemistry, 2006, 41, 114-120.	5.5	24
51	Synthesis and pharmacological studies of new hybrid derivatives of fentanyl active at the Î¼-opioid receptor and I2â€“imidazoline binding sites. Bioorganic and Medicinal Chemistry, 2006, 14, 6570-6580.	3.0	45
52	Study of the structure of 1â€hydroxymethylindazole and 1â€hydroxymethylbenzotriazole by Xâ€ray crystallography, multinuclear NMR in solution and DFT calculations. Journal of Heterocyclic Chemistry, 2004, 41, 285-289.	2.6	13
53	Fentanyl Derivatives Bearing Aliphatic Alkaneguanidinium Moieties: A New Series of Hybrid Molecules with Significant Binding Affinity for Î¼-Opioid Receptors and I2-Imidazoline Binding Sites.. ChemInform, 2004, 35, no.	0.0	0
54	The structure of 1-formyl-3-phenyl-Î”2-pyrazoline in the gas phase (DFT calculations), in solution (NMR) and in the solid state (X-ray crystallography). Journal of Molecular Structure, 2004, 689, 251-254.	3.6	15

#	Article	IF	Citations
55	Fentanyl derivatives bearing aliphatic alkaneguanidinium moieties: a new series of hybrid molecules with significant binding affinity for Î¼-opioid receptors and I2-imidazoline binding sites. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 491-493.	2.2	20
56	Multiple hydrogen bonds and tautomerism in naphthyridine derivatives. New Journal of Chemistry, 2004, 28, 700-707.	2.8	42
57	Discovery of 5-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1H-1,2,4-triazole, a Novel in Vivo Cannabinoid Antagonist Containing a 1,2,4-Triazole Motif. Journal of Medicinal Chemistry, 2004, 47, 2939-2942.	6.4	71
58	Dynamic NMR Study of the Mechanisms of Double, Triple, and Quadruple Proton and Deuteron Transfer in Cyclic Hydrogen Bonded Solids of Pyrazole Derivatives. Journal of the American Chemical Society, 2004, 126, 11718-11732.	13.7	95
59	1,2,4,5-Tetrazines vs. Carboxylic Acid Dimers: Molecular Chemistry vs. Supramolecular Chemistry. Helvetica Chimica Acta, 2003, 86, 1205-1221.	1.6	16
60	The structure of the agrochemical fungicidal 4-chloro-3-(3,5-dichlorophenyl)-1H-pyrazole (RPA 406194) and related compounds. Tetrahedron, 2003, 59, 555-560.	1.9	20
61	Structure of a 4-Nitroso-5-aminopyrazole and Its Salts:Â Tautomerism, Protonation, andE/Zlsomerism. Journal of Organic Chemistry, 2003, 68, 8831-8837.	3.2	21
62	Fentanyl and Its Analogue N-(1-Phenylpyrazol-3-yl)-N-[1-(2-phenylethyl)-4-piperidyl]propanamide: 1H- and 13C-NMR Spectroscopy, X-Ray Crystallography, and Theoretical Calculations. Chemical and Pharmaceutical Bulletin, 2003, 51, 929-934.	1.3	9
63	Synthesis and opioid activity of new fentanyl analogs. Life Sciences, 2002, 71, 1023-1034.	4.3	20
64	Long-Acting Fentanyl Analogues: Synthesis and Pharmacology of N-(1-Phenylpyrazolyl)-N-(1-phenylalkyl-4-piperidyl)propanamides. Bioorganic and Medicinal Chemistry, 2002, 10, 817-827.	3.0	35
65	Guanidinium and aminoimidazolinium derivatives of N-(4-piperidyl)propanamides as potential ligands for Î¼ opioid and I2-imidazoline receptors: synthesis and pharmacological screening. Bioorganic and Medicinal Chemistry, 2002, 10, 1009-1018.	3.0	29
66	An experimental (NMR) and theoretical (GIAO) study of the tautomerism of benzotriazole in solution. Tetrahedron, 2002, 58, 9089-9094.	1.9	48
67	A Solid-State NMR, X-ray Diffraction, and ab Initio Computational Study of Hydrogen-Bond Structure and Dynamics of Pyrazole-4-Carboxylic Acid Chains. Journal of the American Chemical Society, 2001, 123, 7898-7906.	13.7	83
68	Synthesis, X-ray Structure, and Properties of 2-(1â€˜-Pyridin-2â€˜-one)Benzimidazole. Journal of Physical Chemistry B, 2001, 105, 12759-12770.	2.6	9
69	Recent advances in cannabinoid receptor agonists and antagonists. Expert Opinion on Therapeutic Patents, 2000, 10, 1529-1538.	5.0	21
70	A structural study of pyrazole-1-carboxamides by X-ray crystallography and 13C CPMAS NMR spectroscopy. Journal of Molecular Structure, 1999, 478, 81-91.	3.6	4
71	The search for proton mobility in solid pyrazoles: molecular and crystal structure of 3(5)-phenyl-4-bromo-5(3)-methylpyrazole. Journal of Molecular Structure, 1999, 484, 197-205.	3.6	22
72	Synthesis and molecular structure of 3-(2-benzyloxy-6-hydroxyphenyl)-5-styrylpyrazoles. Reaction of 2-styrylchromones and hydrazine hydrate. Tetrahedron, 1999, 55, 10187-10200.	1.9	58

#	Article	IF	Citations
73	Packing Modes in Eight 3-Ethoxycarbonylpyrazole Derivatives. Influence of the Substituents on the Crystal Structure and Annular Tautomerism. Heterocycles, 1999, 50, 227.	0.7	21
74	Hydrogen Bond Compression during Triple Proton Transfer in Crystalline Pyrazoles. A Dynamic ¹⁵N NMR Study. Israel Journal of Chemistry, 1999, 39, 291-299.	2.3	24
75	1,3-Dipolar Cycloaddition of 3-Azido-3-deoxy-1,2:5,6-di-O-isopropylidene-Î±-D-glucofuranose and C60. Journal of Chemical Research, 1999, 23, 680-681.	1.3	0
76	Synthesis and X-ray crystallographic study of 6,12-epiiminodibenzo[b,f][1,5]diazocines. Tetrahedron, 1998, 54, 997-1004.	1.9	22
77	Synthesis and molecular structure of new O/N/O ligands: Bis-phenol-pyridine and bis-phenol-pyrazole. Tetrahedron, 1997, 53, 11645-11658.	1.9	31
78	Solid-state structure of NH-pyrazolium hydrochlorides and hydrobromides by X-ray crystallography and CPMAS NMR. Journal of Molecular Structure, 1997, 415, 81-92.	3.6	10
79	The Unusual Properties of 5â€Methylâ€4,5,6,7â€Tetrahydroâ€1Hâ€Indazole in the Solid State. Chemistry - A European Journal, 1997, 3, 121-126.	3.3	19
80	Synthesis, structure (NMR and mass spectrometry) and conformational analysis of heterocyclic analogues of dibenzo[a,e]cycloocta-1,5-diene: 5,6,12,13-tetrahydrobispyrazolo[1,2-a:1â€²,2â€²-e][1,2,5,6]tetraazocinediium dihalides. Journal of the Chemical Society Perkin Transactions II, 1996, , 701-711.	0.9	14
81	Reaction of 2-azidobenzothiazole and 1-azido-4-(3â€²,5â€²-dimethyl-1â€²-pyrazolyl)tetrafluorobenzene with [60]fullerene and characterization of the adducts by fast-atom bombardment mass spectrometry. Tetrahedron, 1996, 52, 6733-6738.	1.9	12
82	Gas-phase (ion cyclotron resonance spectrometric) and solid-state (crystallographic) studies of highly substituted pyrazoles. Journal of Physical Organic Chemistry, 1996, 9, 79-86.	1.9	7
83	Syntheses and preliminary in vivo photodynamic efficacy of benzoporphyrin derivatives from phylloerythrin and rhodoporphyrin XV methyl esters and aspartyl amides. Tetrahedron, 1996, 52, 5349-5362.	1.9	24
84	New synthetic approaches to condensed pyridazinones: alkylpyridazinyl carbonitriles as building blocks for the synthesis of condensed pyridazinones. Tetrahedron, 1995, 51, 12745-12762.	1.9	55
85	Photosensitization with derivatives of chlorin p6. Journal of Photochemistry and Photobiology B: Biology, 1995, 28, 13-18.	3.8	39
86	The X-ray crystal and molecular structure of 3,5-di-tert-butylpyrazole hydrochloride at 200 K. Journal of Molecular Structure, 1995, 355, 265-271.	3.6	34
87	Solid state structure of NHâ€pyrazoles not easily amenable to crystal structure determinations: The case of 3(5)â€phenylâ€5(3)â€methylpyrazole and 3,5â€diphenylâ€4â€methylpyrazole. Journal of Heterocyclic Chemistry, 1995, 32, 451-456.	2.6	35
88	Synthesis and1H,19F NMR spectroscopic characterization of (pentafluorophenyl)3-n(pyrazol-1-yl-tetrafluorophenyl)n=1,2porphyrins. Journal of Heterocyclic Chemistry, 1995, 32, 1829-1831.	2.6	6
89	Structure and Dynamics of 3,5-Di-tert-butylpyrazole Probed by Combined X-ray Crystallography and 15N Solid State NMR. Journal of Organic Chemistry, 1995, 60, 1965-1970.	3.2	42
90	TRIFLUOROMETHYL AND PERFLUOROALKYL DERIVATIVES OF AZOLES. A REVIEW. Organic Preparations and Procedures International, 1995, 27, 33-74.	1.3	45

#	Article	IF	Citations
91	Aromatic propellenes. Part 1. NMR spectroscopy, X-ray crystal and molecular structure of hexa(3,5-dimethylpyrazol-1-yl)benzene. Journal of the Chemical Society Perkin Transactions II, 1995, , 1359.	0.9	15
92	FAILED ATTEMPT TO INDUCE CHIRALITY USING A MAGNETIC FIELD: THE CASE OF CHIRAL HELICITY OF TRIS-(2-METHYLBENZIMIDAZOL-1-YL)METHANE. Heterocyclic Communications, 1994, 1, .	1.2	4
93	Regioselective synthesis of the homochiral ligand (4S,7R)-7,8,8-trimethyl-4,5,6,7-tetrahydro-4,7-methanoindazol-2-yl-indazol-1â€²-ylmethane. Tetrahedron: Asymmetry, 1994, 5, 1887-1890.	1.8	6
94	15N NMR chemical shifts of NH-pyrazoles in the solid state and in solution at low temperature. Magnetic Resonance in Chemistry, 1994, 32, 699-702.	1.9	38
95	Efficient syntheses of new classes of regiochemically pure benzoporphyrin derivatives. Bioorganic and Medicinal Chemistry Letters, 1993, 3, 2615-2618.	2.2	14
96	Use of the chlorophyll derivative, purpurin-18, for syntheses of sensitizers for use in photodynamic therapy. Journal of the Chemical Society Perkin Transactions 1, 1993, , 2369.	0.9	34
97	Synthesis, spectroscopic and electrochemical characterization of different isomer types in tetrazolatoindium(III) porphyrins. Journal of the Chemical Society Dalton Transactions, 1992, , 1957.	1.1	17
98	Synthesis and characterization of bis(phenyltetrazolato)-germanium(IV) and -tin(IV) porphyrins. Journal of the Chemical Society Dalton Transactions, 1988, , 2569.	1.1	11